Spyre Therapeutics, Inc. (SYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$88.98+1.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SYRE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -14.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SYRE — litigation filed
Dated 2026-08-25
Other Events. On August 25, 2026, the Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. SPY072 SKYWAY-RA Sub-Study Topline Results The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary e…
Why it matters: Good results would show that Spyre's anti-IL-23 therapy can work well.
Supportive ifSPY003 hits its main goal with a strong drop in RHI score.
Worry ifSPY003 fails to meet its primary endpoint or shows no significant improvement.
Why it matters: Good data would show SPY072 might help treat rheumatoid arthritis.
Supportive ifThe RA sub-study shows better clinical remission rates at Week 12.
Worry ifThe RA sub-study does not show much improvement or only meets low standards.
Why it matters: Management's choice not to focus on SPY072 as a single treatment in RA may affect future plans. Watching this will clarify its role.
Watch forManagement plans to move forward with SPY072 in combination treatments for RA.
Also watch forManagement says there are no further plans for SPY072 in any RA treatment.
Why it matters: Keeping a strong cash position is important for funding ongoing trials. Updates will show financial health and ability to operate.
Watch forManagement says cash reserves are steady or increasing. This shows strong financial health.
Also watch forManagement reports a big drop in cash reserves, which may lead to funding problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$212 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $518 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,008 loss on $10,000 · 20.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Progress here may lead to better treatment options. This could affect the company's future.
Supportive ifA press release shows good results for long-lasting antibodies.
Worry ifThere are no updates or bad news about long-acting antibodies for IBD.
Why it matters: These results will show if SPY072 can be effective in more autoimmune diseases. Positive data could support broader use of TL1A antibodies.
Supportive ifData from the PsA and axSpA studies show strong results compared to placebo.
Worry ifData from the PsA and axSpA studies do not show strong results compared to placebo.
Why it matters: Topline data will confirm the efficacy of SPY003 and its potential as a treatment.
Supportive ifSPY003 meets its main goal. It shows a significant drop in the RHI score.
Worry ifSPY003 fails to meet its primary endpoint or shows no significant efficacy.
Why it matters: Good results would show that Spyre's anti-TL1A therapy can work well.
Supportive ifSPY002 shows a statistically significant reduction in RHI score at the 12-week mark.
Worry ifSPY002 fails to meet its primary endpoint or shows no significant improvement.
Why it matters: This data will help us understand SPY003's potential for treating ulcerative colitis. Good results could improve Spyre's position in IBD.
Supportive ifSPY003 meets its main goal with strong results in the Phase 2 trial.
Worry ifSPY003 fails to meet its primary endpoint in the Phase 2 trial.
Why it matters: Enrollment progress shows interest in SPY072 and its chances for success.
Watch forEnrollment in the PsA and axSpA studies ends early.
Also watch forEnrollment in these sub-studies slows or fails to meet expectations.
Why it matters: This data will show if SPY003 can work well for ulcerative colitis. Good results could help Spyre in IBD.
Supportive ifSPY003 shows strong improvement in main goals compared to placebo.
Worry ifSPY003 does not meet main goals or shows no strong improvement compared to placebo.
Why it matters: Cash burn trends will show financial health and how long funds will last.
Worry ifNet cash used in operations goes down compared to past quarters.
Less concerning ifNet cash used in operations goes up a lot, showing worse financial health.
Why it matters: Enrollment in Part B shows strong interest. This may lead to combination therapies in IBD.
Supportive ifEnrollment in Part B is better than expected. It shows strong interest from investigators.
Worry ifEnrollment in Part B is below expectations or slows down a lot.
Why it matters: More losses would show ongoing money problems. This could worry people about the company.
Worry ifQ2 earnings report shows a net income loss greater than $69 million.
Less concerning ifQ2 earnings report shows a net income loss less than or equal to $69 million.
Why it matters: If healthcare sector growth picks up, it could benefit Spyre's performance.
Supportive ifHealthcare sector revenue growth returns to above 10% year over year.
Worry ifHealthcare sector revenue growth is slowing down. It is now below 10% year over year.